A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-2356PMID 19117994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Value of Improving the Productivity of the Drug Development Process

  2012cited by this paper
• Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process

  2012cited by this paper
• Economics of new oncology drug development.

  2007cited by this paper
• Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition

  2007influential reference
• Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

  2006cited by this paper
• Temozolomide: a milestone in neuro-oncology and beyond?

  2006cited by this paper
• Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.

  2005cited by this paper
• The impact of early ADME profiling on drug discovery and development strategy

  2004cited by this paper
• Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors

  2004cited by this paper
• Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

  2004cited by this paper
• Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study

  2004cited by this paper
• Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles

  2003cited by this paper
• Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping.

  2003cited by this paper
• Metabolic activation of temozolomide measured in vivo using positron emission tomography.

  2003cited by this paper
• Economic Evaluation of Vaccination Programmes

  2002cited by this paper
• Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies.

  2002cited by this paper
• Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

  2002cited by this paper
• Temozolomide: a novel oral alkylating agent

  2001cited by this paper
• Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

  2000cited by this paper
• Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

  1999cited by this paper
• Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

  1999cited by this paper
• Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study

  1998influential reference
• Phase I trial of temozolomide using an extended continuous oral schedule.

  1998cited by this paper
• Estimation of Component and Parameter Distributions in Spectral Analysis

  1998cited by this paper
• Activity of temozolomide against human tumor colony-forming units.

  1997cited by this paper
• An Introduction to the Bootstrap

  1995cited by this paper
• The Use of Spectral Analysis to Determine Regional Cerebral Glucose Utilization with Positron Emission Tomography and [18F]Fluorodeoxyglucose: Theory, Implementation, and Optimization Procedures

  1994cited by this paper
• Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

  1993cited by this paper
• Spectral Analysis of Dynamic PET Studies

  1993cited by this paper
• Analytic 3D image reconstruction using all detected events

  1989cited by this paper
• Solving least squares problems

  1976cited by this paper

• Mechanistic Modelling of Transdermal Delivery Dependence on Drug Properties.

  2026cites this paper
• Multiphysics modelling enhanced by imaging and artificial intelligence for personalised cancer nanomedicine: Foundations for clinical digital twins.

  2025cites this paper
• The Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Enhance the Effects of Temozolomide Chemotherapy in Glioblastoma Cells

  2025cites this paper
• Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma

  2025cites this paper
• Analyzing the impact of proliferation and treatment parameters on low-grade glioma growth using mathematical models

  2025cites this paper
• Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma

  2025cites this paper
• A data assimilation framework for predicting the spatiotemporal response of high-grade gliomas to chemoradiation

  2025cites this paper
• Biomimetic Nanosensitizer Potentiates Efficient Glioblastoma Gene-Radiotherapy through Synergistic Hypoxia Mitigation and PLK1 Silencing.

  2024cites this paper
• CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.

  2024cites this paper
• Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro

  2024cites this paper
• Image-based predictive modelling frameworks for personalised drug delivery in cancer therapy.

  2024cites this paper
• Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of Rac-1

  2024cites this paper
• Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1

  2023cites this paper
• Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

  2023cites this paper
• Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study

  2023cites this paper
• Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery.

  2023cites this paper
• The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling

  2023influential citation
• P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma

  2023cites this paper
• Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma

  2023cites this paper
• Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring

  2023cites this paper
• Kaempferol and Biomodified Kaempferol from Sophora japonica Extract as Potential Sources of Anti-Cancer Polyphenolics against High Grade Glioma Cell Lines

  2023cites this paper
• Current therapeutic options for glioblastoma and future perspectives

  2022cites this paper
• Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines

  2022cites this paper
• Tumoricidal, Temozolomide- and Radiation-Sensitizing Effects of KCa3.1 K+ Channel Targeting In Vitro Are Dependent on Glioma Cell Line and Stem Cell Fraction

  2022cites this paper
• Role of Tissue Hydraulic Permeability in Convection-Enhanced Delivery of Nanoparticle-Encapsulated Chemotherapy Drugs to Brain Tumour

  2022cites this paper
• Paciente com glioma focal supera expectativa de vida: relato de caso

  2022cites this paper
• Nanomedicine for Glioblastoma: Progress and Future Prospects.

  2022cites this paper
• Convection-Enhanced Delivery of Antiangiogenic Drugs and Liposomal Cytotoxic Drugs to Heterogeneous Brain Tumor for Combination Therapy

  2022cites this paper
• Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy

  2021cites this paper
• Therapeutic Delivery to Central Nervous System.

  2021cites this paper
• Electrotherapies for Glioblastoma

  2021cites this paper
• A mathematical justification for metronomic chemotherapy in oncology

  2021cites this paper
• Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells

  2021cites this paper
• Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment

  2021cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.

  2021cites this paper
• Image-based personalization of computational models for predicting response of high-grade glioma to chemoradiation

  2021cites this paper
• MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells

  2020cites this paper
• Comparison of absolute protein abundances of transporters and receptors among blood-brain barriers at different cerebral regions and blood-spinal cord barrier in human and rat.

  2020cites this paper
• Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

  2020influential citation
• Brain tumor vessels—a barrier for drug delivery

  2020cites this paper
• The Characterization and Assembly of an Efficient, Cost Effective Focused Ultrasound Transducer

  2020cites this paper
• Recent advances in drug delivery systems for enhancing drug penetration into tumors

  2020cites this paper
• The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology

  2020cites this paper
• A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth

  2020cites this paper
• Brain tumor vessels—a barrier for drug delivery

  2020cites this paper
• ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma

  2020cites this paper
• Role for Metallothionein-3 in the Resistance of Human U87 Glioblastoma Cells to Temozolomide

  2020cites this paper
• Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma

  2020cites this paper
• De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma

  2020cites this paper
• Modelling of Implantable Drug Delivery System in Tumor Microenvironment Using Molecular Communication Paradigm

  2019cites this paper
• Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma

  2019cites this paper
• Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation

  2019cites this paper
• Challenges to curing primary brain tumours

  2019cites this paper
• Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation.

  2019cites this paper
• Mathematical and numerical analysis of low-grade gliomas model and the effects of chemotherapy

  2019cites this paper
• Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway

  2019cites this paper
• Chemotherapeutic Stress Induces Transdifferentiation of Glioblastoma Cells to Endothelial Cells and Promotes Vascular Mimicry

  2019cites this paper
• Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

  2019cites this paper
• Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

  2019cites this paper
• Models of Tumor Growth

  2019cites this paper
• Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma

  2019cites this paper
• Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

  2019cites this paper
• NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/TRIM24

  2019cites this paper
• On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance

  2019cites this paper
• Corrected Proof 3 Feature Article 1 2 Nanoparticle administration across the blood-brain barrier using MRI-guided focused 3 ultrasound 4 5

  2019cites this paper
• Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma

  2018cites this paper
• Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation

  2018cites this paper
• High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma

  2018cites this paper
• 18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.

  2018cites this paper
• Smart niosomes of temozolomide for enhancement of brain targeting

  2018cites this paper
• New Perspectives in Glioblastoma: Nanoparticles-based Approaches.

  2017cites this paper
• Multiplexed imaging for diagnosis and therapy

  2017cites this paper
• Cancer Therapy Optimization based on Unsupervised Learning and Multiple Model Adaptive Control

  2017cites this paper
• A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.

  2017cites this paper
• Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.

  2017cites this paper
• Functional network analysis of gene-phenotype connectivity associated with temozolomide

  2017cites this paper
• Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

  2016cites this paper
• Immune evasion in glioma

  2016cites this paper
• Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response.

  2016cites this paper
• Multimodality imaging and mathematical modelling of drug delivery to glioblastomas

  2016cites this paper
• Imaging Techniques for Evaluation of Drug Distribution in Solid Tumor

  2016cites this paper
• Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature

  2016cites this paper
• Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma

  2016cites this paper
• KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment

  2016cites this paper
• CNS Anticancer Drug Discovery and Development Conference White Paper.

  2015cites this paper
• (99m)Tc-ixolaris targets glioblastoma-associated tissue factor: in vitro and pre-clinical applications.

  2015cites this paper
• Mechanics of the brain: perspectives, challenges, and opportunities

  2015cites this paper
• Brain Pharmacokinetics of Ganciclovir in Rats with Orthotopic BT4C Glioma

  2015cites this paper
• Distribution: Principle, Methods, and Applications

  2015cites this paper
• ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells

  2015cites this paper
• Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide

  2015cites this paper
• Curcumin for the Treatment of Glioblastoma.

  2015cites this paper
• The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence

  2015cites this paper
• A gamma-distribution convolution model of 99mTc-MIBI thyroid time-activity curves

  2015cites this paper
• Non-invasive, real-time reporting drug release in vitro and in vivo.

  2015cites this paper
• Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors

  2015cites this paper
• Modeling of Malignant Glioma and Investigations into Novel Treatments

  2015cites this paper
• Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma

  2014cites this paper
• Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy

  2014cites this paper